AR072777A1 - SOLID FORMS OF BENDAMUSTINE CHLORHYDRATE - Google Patents

SOLID FORMS OF BENDAMUSTINE CHLORHYDRATE

Info

Publication number
AR072777A1
AR072777A1 ARP090101039A ARP090101039A AR072777A1 AR 072777 A1 AR072777 A1 AR 072777A1 AR P090101039 A ARP090101039 A AR P090101039A AR P090101039 A ARP090101039 A AR P090101039A AR 072777 A1 AR072777 A1 AR 072777A1
Authority
AR
Argentina
Prior art keywords
bendamustine
bendamustine hydrochloride
chlorhydrate
solid forms
degrees 2theta
Prior art date
Application number
ARP090101039A
Other languages
English (en)
Inventor
Martin Ian Cooper
Mark Eddleston
Laurent Courvoisier
Robert E Mckean
Original Assignee
Cephalon Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
Priority to US3975208P priority Critical
Application filed by Cephalon Inc filed Critical Cephalon Inc
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41051023&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR072777(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Publication of AR072777A1 publication Critical patent/AR072777A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D235/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D235/16Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/41841,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia

Abstract

Se describe una forma solida de clorhidrato de bendamustina que comprende clorhidrato de bendamustina, Forma 1 y/o clorhidrato de bendamustina, Forma 3 y/o clorhidrato de bendamustina, Forma 4 y/o clorhidrato de bendamustina amorfo, o una mezcla de ellas. La forma solida resultante de clorhidrato de bendamustina tiene un patron de difraccion de rayos X de polvo que contiene una o más de las siguientes reflexiones: 25,1; 24,9; 22,9; 22,0; y/o 14,1 +/- 0,2 grados 2theta; o 26,1; 27,9; y/o 28,1 +/- 0,2 grados 2theta; o 10,8; 15,5; 20,5; y/o 23,6 +/- 0,2 grados 2theta.A solid form of bendamustine hydrochloride comprising bendamustine hydrochloride, Form 1 and / or bendamustine hydrochloride, Form 3 and / or bendamustine hydrochloride, Form 4 and / or amorphous bendamustine hydrochloride, or a mixture thereof is described. The resulting solid form of bendamustine hydrochloride has an X-ray powder diffraction pattern that contains one or more of the following reflections: 25.1; 24.9; 22.9; 22.0; and / or 14.1 +/- 0.2 degrees 2theta; or 26.1; 27.9; and / or 28.1 +/- 0.2 degrees 2theta; or 10.8; 15.5; 20.5; and / or 23.6 +/- 0.2 degrees 2theta.
ARP090101039A 2008-03-26 2009-03-23 SOLID FORMS OF BENDAMUSTINE CHLORHYDRATE AR072777A1 (es)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US3975208P true 2008-03-26 2008-03-26

Publications (1)

Publication Number Publication Date
AR072777A1 true AR072777A1 (es) 2010-09-22

Family

ID=41051023

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP090101039A AR072777A1 (es) 2008-03-26 2009-03-23 SOLID FORMS OF BENDAMUSTINE CHLORHYDRATE

Country Status (12)

Country Link
US (9) US20090264488A1 (es)
EP (2) EP3150197A1 (es)
JP (1) JP5536753B2 (es)
CN (3) CN101980698B (es)
AR (1) AR072777A1 (es)
CA (1) CA2718939A1 (es)
CL (1) CL2009000742A1 (es)
ES (1) ES2605205T3 (es)
HK (1) HK1220966A1 (es)
MX (2) MX2010010398A (es)
TW (1) TWI472515B (es)
WO (1) WO2009120386A2 (es)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8436190B2 (en) 2005-01-14 2013-05-07 Cephalon, Inc. Bendamustine pharmaceutical compositions
US8975284B2 (en) * 2007-10-09 2015-03-10 Us Worldmeds Llc Co-solvent compositions and methods for improved delivery of dantrolene therapeutic agents
AR072777A1 (es) 2008-03-26 2010-09-22 Cephalon Inc SOLID FORMS OF BENDAMUSTINE CHLORHYDRATE
MX2011002936A (es) * 2008-09-25 2011-04-11 Cephalon Inc Formulaciones liquidas de bendamustina.
NZ592971A (en) * 2008-12-03 2013-08-30 Astellas Deutschland Gmbh Solid dosage forms of bendamustine
WO2010144675A1 (en) * 2009-06-10 2010-12-16 Plus Chemicals Sa Polymorphs of bendamustine hcl and processes for preparation thereof
WO2011079193A2 (en) * 2009-12-23 2011-06-30 Dr. Reddy's Laboratories Ltd. Preparation of bendamustine and its salts
PL2528602T5 (pl) 2010-01-28 2020-09-07 Eagle Pharmaceuticals, Inc. Preparaty bendamustyny
AU2011260615B2 (en) 2010-06-02 2016-11-17 Astellas Deutschland Gmbh Oral dosage forms of bendamustine
JO3659B1 (ar) 2010-06-02 2020-08-27 Astellas Deutschland Gmbh أشكال جرعات بينداموستين عن طريق الفم وإستخداماته العلاجية
CN101948437B (zh) * 2010-06-28 2012-08-29 江苏奥赛康药业股份有限公司 一种盐酸苯达莫司汀的精制方法
US20130217888A1 (en) 2010-11-01 2013-08-22 Shailpa Medicare Limited Process for preparing bendamus tine hydrochloride monohydrate
WO2012103226A2 (en) * 2011-01-25 2012-08-02 Dr. Reddy's Laboratories Ltd. Bendamustine formulations
CA2819017A1 (en) * 2011-01-31 2012-08-09 Cephalon, Inc. Methods for the preparation of bendamustine
CN104011029B (zh) 2011-09-26 2016-06-08 费森尤斯卡比肿瘤学有限公司 一种制备盐酸苯达莫司汀的改进方法
CN102351799B (zh) * 2011-10-24 2014-02-26 江苏奥赛康药业股份有限公司 一种盐酸苯达莫司汀晶型及其制备方法
EP2617716A1 (en) 2012-01-18 2013-07-24 Arevipharma GmbH Process for the preparation of bendamustine hydrochloride and related compounds
LT2827863T (lt) 2012-03-20 2019-06-10 Eagle Pharmaceuticals, Inc. Skysta kompozicija, skirta panaudoti bendamustinui jautrių būklių gydymo būde pacientuose, kuriems reikalingi sumažinti įvedimo tūriai
WO2013142358A1 (en) 2012-03-20 2013-09-26 Eagle Pharmaceuticals, Inc. Formulations of bendamustine
WO2013150020A1 (en) 2012-04-03 2013-10-10 Synthon Bv Process for making bendamustine
DK2656843T3 (en) 2012-04-26 2015-04-20 Helmut Schickaneder Esters of bendamustine and related compounds, and medical use thereof
US9801859B2 (en) * 2012-09-18 2017-10-31 Innopharma Licensing, Llc Bendamustine formulations
JP6262246B2 (ja) 2012-11-12 2018-01-17 イグニタ、インク. ベンダムスチン誘導体およびこれを使用する方法
EP2958554B1 (en) 2013-02-19 2018-06-06 Synthon BV Stable compositions of bendamustine
US9315469B2 (en) 2013-03-14 2016-04-19 Johnson Matthey Public Limited Company Process for drying bendamustine hydrochloride monohydrate
WO2014170769A2 (en) * 2013-04-15 2014-10-23 Shilpa Medicare Limited Bendamustine lyophilized pharmaceutical compositions
JP6571657B2 (ja) 2013-08-27 2019-09-04 ボウドウリス バシリオス ベンダムスチンの薬学的組成物
WO2015138199A1 (en) 2014-03-13 2015-09-17 Voudouris Vasilios Bendamustine solid dispersions and continuous infusion
EP2985038A1 (en) 2014-08-12 2016-02-17 Azad Pharma AG Lyophilized API preparation
US10342769B2 (en) 2014-11-14 2019-07-09 Navinta Iii Inc Carmustine pharmaceutical composition
US9603930B2 (en) 2014-12-04 2017-03-28 Navinta, Llc Liquid bendamustine formulation
AU2016274757B2 (en) * 2015-06-09 2019-02-07 Rebiotix, Inc. Microbiota restoration therapy (MRT) compositions and methods of manufacture
US10905677B2 (en) 2016-08-31 2021-02-02 Navinta, Llc Bendamustine solution formulations
EP3691637A1 (en) 2017-10-05 2020-08-12 TUBE Pharmaceuticals GmbH Oral bendamustine formulations
CN111093654A (zh) * 2017-11-07 2020-05-01 江苏恒瑞医药股份有限公司 一种盐酸苯达莫司汀的晶体及其制备方法
EA037673B1 (ru) * 2018-07-04 2021-04-29 Тютор С.А.С.И.Ф.И.А. Способ получения фармацевтической композиции, содержащей бендамустин, фармацевтическая композиция бендамустина

Family Cites Families (81)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE34727C (es)
DE159289C (es) 1903-10-08 1905-03-16
DE159877C (es) *
DE80967C (es)
DD80967A (es)
DE293808C (es)
DD34727A1 (de) 1963-12-21 1964-12-28 Dietrich Krebs Verfahren zur Herstellung von 1-Stellung substituierten [5-Bis-(chloräthyl)-amino-benzimidazolyl-(2)]-alkancarbonsäuren
YU33730B (en) 1967-04-18 1978-02-28 Farmaceutici Italia Process for preparing a novel antibiotic substance and salts thereof
US4012448A (en) 1976-01-15 1977-03-15 Stanford Research Institute Synthesis of adriamycin and 7,9-epiadriamycin
DD159289A1 (de) 1981-06-01 1983-03-02 Uwe Olthoff Verfahren zur herstellung stabiler injektionsloesungen von n-lostverbindungen
DD159877A1 (de) * 1981-06-12 1983-04-13 Wolfgang Krueger Verfahren zur herstellung von 4-[1-methyl-5-bis(2-chloraethyl)amino-benzimidazolyl-2]-buttersaeure
IT1153974B (it) 1982-09-23 1987-01-21 Erba Farmitalia Composizioni farmacologiche a base di cisplatino e metodo per il loro ottenimento
US4537883A (en) 1982-11-12 1985-08-27 Mead Johnson & Company Lyophilized cyclophosphamide
US5227374A (en) 1982-11-12 1993-07-13 Mead Johnson & Company Lyophilized cyclophosphamide
US4659699A (en) 1983-08-22 1987-04-21 Cetus-Ben Venue Therapeutics Process for freeze drying cyclophosphamide
US5183746A (en) 1986-10-27 1993-02-02 Schering Aktiengesellschaft Formulation processes for pharmaceutical compositions of recombinant β-
US5204335A (en) * 1986-10-31 1993-04-20 Asta Pharma Aktiengesellschaft Ifosfamide lyophilisate and process for its preparation
US4879286A (en) 1987-01-28 1989-11-07 Lyphomed, Inc. Cyclophosphamide
DE3907079A1 (de) 1988-03-19 1989-09-28 Asta Pharma Ag Ifosfamid-mesna-lyophilisat und verfahren zu dessen herstellung
EP0334083B1 (de) 1988-03-19 1991-07-24 ASTA Pharma Aktiengesellschaft Ifosfamid-Mesna-Lyophilisat und Verfahren zu dessen Herstellung
US5036060A (en) 1988-07-25 1991-07-30 Fujisawa Usa, Inc. Cyclophosphamide
CA2001552C (en) 1988-11-14 1997-07-22 The Upjohn Company Cyclophosphamide - sodium bicarbonate lyophilizates
US5066647A (en) 1989-04-20 1991-11-19 Erbamont, Inc. Cyclophosphamide - alanine lyophilizates
US5051257A (en) 1989-05-09 1991-09-24 Pietronigro Dennis D Antineoplastic solution and method for treating neoplasms
DD293808A5 (de) 1990-04-23 1991-09-12 Zi Fuer Mikrobiologie Uns Experimentelle Therapie,De Verfahren zur herstellung von (5-[bis(2-chlorethyl)amino]-1-methyl-benzimidazolyl(2)ethansaeurealkylestern
US5268368A (en) 1991-05-17 1993-12-07 Erbamont, Inc. Cyclophosphamide--amino acid lyophilizates
US5227373A (en) * 1991-10-23 1993-07-13 Bristol-Myers Squibb Co. Lyophilized ifosfamide compositions
US5418223A (en) 1993-05-20 1995-05-23 Erbamont, Inc. Method for lyophilization of cyclophosphamide and product
US5192743A (en) 1992-01-16 1993-03-09 Genentech, Inc. Reconstitutable lyophilized protein formulation
MD1367C2 (ro) * 1992-11-13 2000-11-30 Idec Pharmaceuticals Corporation Metode de tratament al limfomului celulelor B, anticorpi anti-CD20, hibridom.
US5595721A (en) * 1993-09-16 1997-01-21 Coulter Pharmaceutical, Inc. Radioimmunotherapy of lymphoma using anti-CD20
CN1060042C (zh) * 1993-10-27 2001-01-03 法玛西雅厄普约翰美国公司 稳定的前列腺素e1
US5561121A (en) 1993-11-09 1996-10-01 American Cyanamid Company Stable lyophilized thiotepa composition
US5955504A (en) * 1995-03-13 1999-09-21 Loma Linda University Medical Center Colorectal chemoprotective composition and method of preventing colorectal cancer
DE19529057B4 (de) * 1995-08-08 2007-12-13 Baxter Healthcare S.A. Ifosfamid-Lyophilisat-Zubereitungen
JPH11511463A (ja) 1995-08-31 1999-10-05 スミスクライン・ビーチャム・コーポレイション インターロイキン変換酵素およびアポプトーシス
DK0780386T3 (da) 1995-12-20 2003-02-03 Hoffmann La Roche Matrixmetalloproteaseinhibitorer
US6261537B1 (en) 1996-10-28 2001-07-17 Nycomed Imaging As Diagnostic/therapeutic agents having microbubbles coupled to one or more vectors
US20040072889A1 (en) * 1997-04-21 2004-04-15 Pharmacia Corporation Method of using a COX-2 inhibitor and an alkylating-type antineoplastic agent as a combination therapy in the treatment of neoplasia
US6077850A (en) * 1997-04-21 2000-06-20 G.D. Searle & Co. Substituted benzopyran analogs for the treatment of inflammation
US6034256A (en) * 1997-04-21 2000-03-07 G.D. Searle & Co. Substituted benzopyran derivatives for the treatment of inflammation
EA200000087A1 (ru) 1997-07-01 2000-08-28 Атеродженикс, Инк. Повышение эффективности терапии гиперпролиферативных состояний с помощью антиоксиданта
GB9803448D0 (en) 1998-02-18 1998-04-15 Pharma Mar Sa Pharmaceutical formulation
CA2336932A1 (en) * 1998-07-09 2000-01-20 Francis A. Nardella Methods and compositions for the treatment of chronic lymphocytic leukemia
US6689600B1 (en) 1998-11-16 2004-02-10 Introgen Therapeutics, Inc. Formulation of adenovirus for gene therapy
US5972912A (en) * 1998-12-17 1999-10-26 S.P. Pharmaceuticals Method for lyophilizing ifosfamide
US6569402B1 (en) * 1998-12-18 2003-05-27 Bristol-Myers Squibb Pharma Company Vitronectin receptor antagonist pharmaceuticals
US6380210B1 (en) * 1999-04-02 2002-04-30 Neurogen Corporation Heteroaryl fused aminoalkyl-imidazole derivatives: selective modulators of GABAa receptors
US6545034B1 (en) * 1999-07-23 2003-04-08 The Regents Of The University Of California Use of etodolac for the treatment of chronic lymphocytic leukemia
US20040152672A1 (en) * 2000-08-09 2004-08-05 Carson Dennis A. Indole compounds useful for the treatment of cancer
DE10016077A1 (de) 2000-03-31 2001-12-13 Cellcontrol Biomedical Lab Gmb Verfahren und Vorrichtung zum automatischen Nachweisen einer Wirkung eines zellbeeinflussenden Mittels auf lebende Zellen
AUPQ849900A0 (en) 2000-06-30 2000-07-27 Dbl Australia Pty Ltd. Injectable composition
AU2111502A (en) * 2000-12-11 2002-06-24 Takeda Chemical Industries Ltd Medicinal compositions having improved absorbability
EP1350792A1 (en) * 2000-12-11 2003-10-08 Takeda Chemical Industries, Ltd. Medicinal compositions improved in solublity in water
WO2002080996A1 (de) * 2001-04-03 2002-10-17 Franz Herbst Medizinisches implantat und verfahren zu seiner herstellung
CN1568166A (zh) * 2001-10-15 2005-01-19 荷姆泰克股份有限公司 预防再狭窄的涂层支架
US6613927B1 (en) * 2002-02-08 2003-09-02 American Pharmaceutical Partners, Inc. Sterile lyophilized ifosfamide and associated methods
DE10306724A1 (de) 2002-02-28 2003-09-18 G O T Therapeutics Gmbh Vesikuläre Verkapselung von Bendamustin
US6780324B2 (en) 2002-03-18 2004-08-24 Labopharm, Inc. Preparation of sterile stabilized nanodispersions
AT389183T (de) 2002-03-22 2008-03-15 Univ Muenchen L Maximilians Zytokapazität-verfahren
EP1354952A1 (en) 2002-04-17 2003-10-22 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Smac-peptides as therapeutics against cancer and autoimmune diseases
WO2003086470A2 (en) 2002-04-17 2003-10-23 Deutsches Krebsforschungszentrum Smac-peptides as therapeutics against cancer and autoimmune diseases
AT404232T (de) * 2002-05-09 2008-08-15 Hemoteq Ag Hemokompatibel beschichtete medizinprodukte, deren herstellung und verwendung
NZ540318A (en) 2002-10-31 2007-09-28 Umd Inc Therapeutic compositions for drug delivery to and through covering epithelia
US20040096436A1 (en) * 2002-08-02 2004-05-20 Regents Of The University Of California Methods for inhibiting protein kinases in cancer cells
DE10304403A1 (de) 2003-01-28 2004-08-05 Röhm GmbH & Co. KG Verfahren zur Herstellung einer oralen Arzneiform mit unmittelbarem Zerfall und Wirkstofffreisetzung
EP1444989A1 (en) 2003-02-07 2004-08-11 Giorgio Dr. Stassi Sensitizing cells for apoptosis by selectively blocking cytokines
WO2004074325A2 (en) * 2003-02-14 2004-09-02 Salmedix, Inc Compositions and methods for the detection and treatment of methylthioadenosine phosphorylase deficient cancers
CA2532251A1 (en) * 2003-07-25 2005-02-10 Wyeth Cci-779 lyophilized formulations
JP2008519047A (ja) 2004-11-05 2008-06-05 セフアロン・インコーポレーテツド 癌処置
MX2007006106A (es) 2004-11-22 2007-10-23 Venus Remedies Ltd Formulacion liquida parenteral no acuosa de aceclofenaco.
EP1674081A1 (de) * 2004-12-23 2006-06-28 KTB Tumorforschungsgesellschaft mbH Herstellung von lipidbasierten Nanopartikeln unter Einsatz einer dualen asymmetrischen Zentrifuge
US8436190B2 (en) 2005-01-14 2013-05-07 Cephalon, Inc. Bendamustine pharmaceutical compositions
CN101119708B (zh) * 2005-01-14 2014-12-24 赛福伦公司 苯达莫司汀冻干药物组合物
US7872050B2 (en) 2005-03-14 2011-01-18 Yaupon Therapeutics Inc. Stabilized compositions of volatile alkylating agents and methods of using thereof
EP1909824B1 (en) 2005-04-08 2011-05-18 Amylin Pharmaceuticals, Inc. Pharmaceutical formulations comprising incretin peptide and aprotic polar solvent
US8158152B2 (en) 2005-11-18 2012-04-17 Scidose Llc Lyophilization process and products obtained thereby
ITUD20070130A1 (it) 2007-07-23 2009-01-24 C M E Spa Sa Macchina e procedimento per la produzione di elementi strutturali per l'edilizia in materiale cementizio aventi uno o piu' inserti in materiale polimerico
AR072777A1 (es) 2008-03-26 2010-09-22 Cephalon Inc SOLID FORMS OF BENDAMUSTINE CHLORHYDRATE
MX2011002936A (es) 2008-09-25 2011-04-11 Cephalon Inc Formulaciones liquidas de bendamustina.
CA2760085A1 (en) 2009-04-28 2010-11-04 Cephalon, Inc. Oral formulations of bendamustine

Also Published As

Publication number Publication date
US20150051258A1 (en) 2015-02-19
CN103550159B (zh) 2016-02-10
WO2009120386A2 (en) 2009-10-01
MX2010010398A (es) 2010-12-20
US20130245086A1 (en) 2013-09-19
EP2271315A2 (en) 2011-01-12
US8883836B2 (en) 2014-11-11
HK1220966A1 (zh) 2017-05-19
US20120071532A1 (en) 2012-03-22
EP3150197A1 (en) 2017-04-05
US8445524B2 (en) 2013-05-21
TW200944508A (en) 2009-11-01
CA2718939A1 (en) 2009-10-01
JP5536753B2 (ja) 2014-07-02
US20200323824A1 (en) 2020-10-15
MX339878B (es) 2016-06-15
US20170071913A1 (en) 2017-03-16
US10517852B2 (en) 2019-12-31
CN101980698B (zh) 2013-10-16
EP2271315B1 (en) 2016-09-14
US8669279B2 (en) 2014-03-11
US10039750B2 (en) 2018-08-07
US20160159748A1 (en) 2016-06-09
CL2009000742A1 (es) 2009-11-13
CN101980698A (zh) 2011-02-23
JP2011515472A (ja) 2011-05-19
ES2605205T3 (es) 2017-03-13
CN105693620A (zh) 2016-06-22
US9533955B2 (en) 2017-01-03
CN103550159A (zh) 2014-02-05
WO2009120386A3 (en) 2009-12-03
US20140187598A1 (en) 2014-07-03
US20190015390A1 (en) 2019-01-17
US20090264488A1 (en) 2009-10-22
TWI472515B (zh) 2015-02-11

Similar Documents

Publication Publication Date Title
ES2605205T3 (es) Solid forms of bendamustine hydrochloride
AR072087A1 (es) Construccion de correa draper para controlar la traslacion
AR073631A1 (es) Antagonistas del receptor transitorio potencial de vanilloides 1 ( trpv1) utiles para tratar inflamacion y dolor
AR072262A1 (es) COMBINACION -408, QUE COMPRENDE N-CICLOHEXIL-N3-[2-(3-FLUOROFENIL)ETIL]-N-(2-{[2-(4-HIDROXI-2-OXO-2,3-DIHIDRO-1,3-BENZOTIAZOL-7-IL)ETIL]AMINO}ETIL- beta-ALANINAMIDA.USO. METODO. CONJUNTO DE ELEMENTOS. COMPOSICION FARMACEUTICA. INTERMEDIARIO.
AR073590A1 (es) CURING COMPOSITION TO COVER COMPOUND MATERIALS
AR071878A1 (es) POWDER INHALER
AR071016A1 (es) Mecanismo de preparacion de bebidas
AR073964A1 (es) Composiciones que comprenden acido 4-(2-(5-bromo-4-(1-ciclopropilnaftalen -4-il) -4h- 1,2,4-triazol-3-il tio ) acetamido)-3-clorobenzoico y sus sales farmaceuticamente aceptables y metodos de preparacion y uso delos mismos
AR072453A1 (es) Metodo y aparato para preparar una solucion de un material sensible al esfuerzo de corte
AR074320A1 (es) Cuba de madera mejorada
AR073746A1 (es) Dispositivo de acoplamiento y desacople de un embrague de una maquina de lavar ropa
AR072966A1 (es) Sistema y metodos de control de aplicaciones de escritorio basado en la web
AR069273A1 (es) Maquina motriz
AR063002A1 (es) Utilizacion de la gonadotrofina corionica humana (gch) por via oral sublingual o inyectable como agente supresor del apetito
AR062803A1 (es) Patilla de anteojos porta dispositivo de almacenamiento portatil con memoria no volatil (pendrives)
AR062802A1 (es) Maquina flotante para generacion de energia
AR064328A4 (es) Dispositivo de transporte urbano para reparto de correo u otras cargas a domicilio
AR062244A1 (es) Disposicion para calentamiento de hidrocarburos en tuberias de transporte por emision de ondas electromagneticas
AR061683A1 (es) Uso de la gonadotrofina corionica humana (gch) asociada a una ciclodextrina, por via oral-sublingual o inyectable intramuscular, para el tratamiento de las diferentes manifestaciones clinicas y de laboratorio del ovario poliquistico (pco)
AR061948A1 (es) Una herramienta y metodo mejorados para el corte y remocion de tapones puente de material compuesto
AR064948A1 (es) Disposicion para realizar ensayos de traccion en anclajes
AR061781A1 (es) Sistema integral de tratamiento, recuperacion y potabilizacion de agua
AR062540A1 (es) Un cubre auto retractil
AR064933A4 (es) Ojotas sin capellada, adherentes al pie
AR064912A1 (es) Dispositivo portaestuche regulable

Legal Events

Date Code Title Description
FC Refusal